Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 545–552 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
ArriVent BioPharma Inc. Furmonertinib - (FURVENT) 1L advanced or metastatic NSCLC with EGFR exon 20 insertion mutations Phase 3 Ongoing Oral Oncology
Arrowhead Pharmaceuticals Inc. Olpasiran (AMG 890) - (OCEAN(a)-DOSE) Cardiovascular disease / Elevated Lipoprotein Phase 3 Trial Planned Subcutaneous Cardiology
Arrowhead Pharmaceuticals Inc. Fazirsiran (TAK-999/ARO-AAT) - (REDWOOD) Alpha-1 antitrypsin deficiency (AATD-LD) NDA Filing Data Released Intravenous Genetic Disorder
Arrowhead Pharmaceuticals Inc. Plozasiran (ARO-APOC3) - (CAPITAN) Mixed hyperlipidemia Phase 3 Trial Planned Subcutaneous Cardiology
Arrowhead Pharmaceuticals Inc. Plozasiran (ARO-APOC3) - (CAPITAN) Mixed hyperlipidemia Phase 3 Trial Planned Subcutaneous Cardiology
Arrowhead Pharmaceuticals Inc. Fazirsiran (ARO-AAT) - (SEQUOIA) Alpha-1 Liver Disease Phase 2/3 Ongoing Subcutaneous Genetic Disorder
Arrowhead Pharmaceuticals Inc. Olpasiran (AMG 890) - (OCEAN(a)-DOSE) Cardiovascular disease / Elevated Lipoprotein Phase 3 Trial Planned Subcutaneous Cardiology
Arrowhead Pharmaceuticals Inc. Plozasiran (ARO-APOC3) - (CAPITAN) Mixed hyperlipidemia Phase 3 Trial Planned Subcutaneous Cardiology